KYBORA, a global healthcare advisory firm and investment bank, is proud to announce that Vladyslava Bab’yak has joined the company as an Analyst. With a double Master’s degree in Finance with honors from the School of Business, Economics and Law in Gothenburg, and the University of Rome Tor Vergata, Vladyslava brings an analytical mindset and international […]
Episode 2: Biopharma Today: Tariff Pressures and Industry Transformation In our second episode, Biopharma Today: Tariff Pressures and Industry Transformation, host Alan Vanderborght, CEO of KYBORA, welcomes guest Carlo de Notaristefani, President at CDN Advising.They engage in a discussion about Carlo’s extensive experience, supply chain management, tariff pressures and the evolution of the Biopharma industry. […]
A Strategic Vision for Healthcare Expansion – Setting the stage for continued growth in 2025 For many small and medium-sized enterprises (SMEs) in the life sciences sector, the path to scaling up, innovation and expansion can be blocked by regional limitations, resource constraints, and the complexities of global markets access. This was the case for […]
The biotech industry has experienced a dramatic shift since 2022. After the pandemic-era boom, the sector entered a “tumble” marked by slashed budgets, reduced headcounts, and cautious financial stewardship (6 Predictions for Healthcare and Biotech in 2024｜Audacity Health). Small to mid-sized biotech companies – from early-stage startups to publicly traded micro-caps – now face a […]
Princeton, NJ – April 10th, 2025 – KYBORA, a global healthcare advisory firm and investment bank, is proud to announce that Erik Heinnickel, has joined the company as Senior Director Operations. With nearly two decades of experience in analytics and operational leadership across pharmaceuticals, biotech, and other industries, Erik brings a data-driven, collaborative approach to building […]
Trends, Insights, and Strategic Implications The first quarter of 2025 marked a dynamic start to the year for the biopharma sector, continuing momentum from 2024’s wave of transformative transactions. Mergers and acquisitions (M&A), strategic licensing agreements, and novel collaborations were driven by three core themes: expansion in oncology, growing investment in immunology and neurology, and […]
Key Trends and Insights Global Out-Licensing and Partnerships In 2024, the biopharma sector saw a remarkable resurgence in activity, driven by global licensing and partnerships. The U.S. led the market with $7.0 billion across 373 deals, followed by the EMEA with $3.9 billion in 167 deals and the APAC region with $3.0 billion in 133 […]
Transforming Medicine Oligonucleotide-based therapeutics are rapidly emerging as a transformative class of drugs, capable of targeting previously untreatable diseases at their genetic roots. These molecules, encompassing antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and mRNA-based therapies, work by modulating gene expression with unparalleled precision. The global antisense oligonucleotide (ASO) drug market has experienced significant growth, […]
Transforming Precision Medicine with Targeted Therapies Radiopharmaceuticals are transforming precision medicine by offering targeted diagnostic and therapeutic solutions. These innovative treatments focus radiation on diseased tissues, minimizing damage to healthy cells. With significant advancements in diagnostics, theranostics, and radionuclide therapies, radiopharmaceuticals are transforming oncology, cardiology, and neurology. Despite challenges like isotope supply constraints and infrastructure […]
Episode 1: The Science and Business Behind Healthcare In the first episode of our podcast, host Alan Vanderborght, CEO of KYBORA, welcomes guest John Gregg, Chairman and CEO at BalinBac Therapeutics, for an engaging conversation about his extensive experience in the industry. They discuss the evolution of Healthcare, groundbreaking scientific innovations and the trends shaping […]
